1 / 6

Global Biosimilars industry size is expected to increase significantly by 2024

The global biosimilars market size was valued at 3.39 billion in 2016 and is expected to grow on account of increasing prevalence of chronic diseases such as cancer and autoimmune disorders.

Carrol
Télécharger la présentation

Global Biosimilars industry size is expected to increase significantly by 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Your Catalyst To a Lucrative Business Biosimilars Market Research Report - Global Industry Analysis, Size, Growth and Forecast to 2024 – Hexa Research “Global Biosimilars market size was valued at 3.39 billion in 2016 and is expected to grow on account of increasing prevalence of chronic diseases such as cancer and autoimmune disorders..” The Global Biosimilars Market is expected to reach USD 13.1 billion by 2024 on account of increase in the prevalence of chronic diseases such as cancer, diabetics, cardiac disorders and autoimmune diseases. Rising demand for the cost- effective therapies is expected to drive the market in the forecast period. Biosimilars are about 30% cheaper than their counterpart biologics. Furthermore, the patent expiry of the blockbuster drugs is anticipated to provide a lucrative opportunity for the growth of biosimilars. For instance, a patent for Bevacizumab, sold under the trade name Avastin is expiring in 2019. Moreover, increasing government initiatives, speedy drug approvals and reimbursement policies are expected to boost the market for the biosimilars in the study period. Also, market giants are adopting merger & acquisition strategies to increase their product portfolio. For instance, in 2015, Pfizer, Inc. acquired Hospira, a key player in biosimilars market. Browse Details of Report @ https://www.hexaresearch.com/research-report/biosimilars-market In 2016, oncology was the largest segment, accounting for 32% market share. Increasing prevalence of cancer across the globe is the key factor driving the growth of the market over the forecast period. For instance, according to the American Cancer Society, an estimated 1.6 lakh people suffered from cancer in 2016. Also, increasing government initiatives to provide cost effective treatment to cure deadly diseases will boost the penetration of biosimilar in developing countries which in turn will increase the market for biosimilar over the forecast period. For instance, WHO launched a pilot program for prequalifying biosimilar drug, making some of the most expensive treatments for cancer Follow Us:

  2. Your Catalyst To a Lucrative Business more widely available in developing countries. Under this initiative, WHO has focused on two essential drug rituximab (principally used for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia), and trastuzumab (for the treatment of breast cancer). In terms of region, Europe dominates the market for biosimilars followed by North America. The dominance of Europe is due speedy approval of the drug by European regulatory bodies. Furthermore, improving healthcare infrastructure and ageing population is expected to drive the market over the forecast period. However, Asia Pacific is projected to be the fastest growing region owing to the increasing disposable income of middle-class families, growing medical tourism and improving healthcare infrastructure. Furthermore, increasing investment in R&D activities by pharmaceutical giants is expected to boost the market in the projected period. Hexa Research has segmented the global biosimilars market based on indication and region: Segmentation by indication, 2014 - 2024 (USD Million) • Blood Disorders • Oncology • Chronic & Autoimmune Diseases • Others Segmentation by region, 2014 - 2024 (USD Million) • North America • U.S. • Europe • Germany • Asia Pacific • China • India • Japan • Rest of the world Key players analyzed: • Dr. Reddy’s Laboratories Ltd • Mylan • Shanghai Fosun Pharmaceutical (Group) Co., Ltd. • Pfizer Inc. • Sandoz International GmbH • Teva Pharmaceuticals Industries Ltd. • Amgen Inc. • STADA Arzneimittel AG • Biocon • F. Hoffmann-La Roche Ltd. Browse Related Category Market Reports@ https://www.hexaresearch.com/research-category/healthcare- industry Follow Us:

  3. Your Catalyst To a Lucrative Business Table of Content of Biosimilars Market Chapter 1. Market Summary 1.1. Market trends & movement Chapter 2. Global Biosimilars Market Trends: Drivers & Opportunities 2.1. Introduction 2.2. Key industry trends 2.3. Market drivers 2.4. Market restraints 2.5. Value chain analysis 2.6. Porter's Five Forces analysis 2.7. SWOT Chapter 3. Global Biosimilars Market Trends, By Indication 3.1. Global Biosimilars market movement, by indication, 2016 & 2024 3.1.1. Blood disorders 3.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million) 3.1.2. Oncology 3.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million) 3.1.3. Chronic & Autoimmune Diseases 3.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million) 3.1.4. Others 3.1.4.1. Market estimates and forecast, 2014 - 2024 (USD Million) Chapter 4. Global Automotive Suspension Market Trends, By Region 4.1. Global automotive suspension market movement, by region, 2016 & 2024 4.1.1. North America 4.1.1.1. Market estimates and forecast, 2014 - 2024 (USD Million) 4.1.1.2. Market estimates and forecast, by indication, 2014 - 2024 (USD Million) 4.1.2. Europe 4.1.2.1. Market estimates and forecast, 2014 - 2024 (USD Million) 4.1.2.2. Market estimates and forecast, by indication, 2014 - 2024 (USD Million) 4.1.3. Asia Pacific 4.1.3.1. Market estimates and forecast, 2014 - 2024 (USD Million) 4.1.3.2. Market estimates and forecast, by indication, 2014 - 2024 (USD Million) 4.1.4. Rest of the World 4.1.4.1. Market estimates and forecast, 2014 - 2024 (USD Million) 4.1.4.2. Market estimates and forecast, by indication, 2014 - 2024 (USD Million) Follow Us:

  4. Your Catalyst To a Lucrative Business Chapter 5. Competitive Landscape 5.1. Competitive landscape analysis, 2016 5.2. Strategic framework 5.3. Potential customer base concentration 5.4. Company market positioning 5.5. Company profiles 5.5.1. Dr. Reddy’s Laboratories Ltd. 5.5.1.1. Company Overview 5.5.1.2. Product Benchmarking 5.5.1.3. Financial Performance 5.5.1.4. Recent Initiatives 5.5.2. Mylan 5.5.2.1. Company Overview 5.5.2.2. Product Benchmarking 5.5.2.3. Financial Performance 5.5.2.4. Recent Initiatives 5.5.3. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 5.5.3.1. Company Overview 5.5.3.2. Product Benchmarking 5.5.3.3. Financial Performance 5.5.3.4. Recent Initiatives 5.5.4. Pfizer Inc. 5.5.4.1. Company Overview 5.5.4.2. Product Benchmarking 5.5.4.3. Financial Performance 5.5.4.4. Recent Initiatives 5.5.5. Sandoz International GmbH 5.5.5.1. Company Overview 5.5.5.2. Product Benchmarking 5.5.5.3. Financial Performance 5.5.5.4. Recent Initiatives 5.5.6. Teva Pharmaceuticals Industries Ltd. 5.5.6.1. Company Overview 5.5.6.2. Product Benchmarking 5.5.6.3. Financial Performance 5.5.6.4. Recent Initiatives Follow Us:

  5. Your Catalyst To a Lucrative Business 5.5.7. Amgen Inc. 5.5.7.1. Company Overview 5.5.7.2. Product Benchmarking 5.5.7.3. Financial Performance 5.5.7.4. Recent Initiatives 5.5.8. STADA Arzneimittel AG 5.5.8.1. Company Overview 5.5.8.2. Product Benchmarking 5.5.8.3. Financial Performance 5.5.8.4. Recent Initiatives 5.5.9. Biocon 5.5.9.1. Company Overview 5.5.9.2. Product Benchmarking 5.5.9.3. Financial Performance 5.5.9.4. Recent Initiatives 5.5.10. F. Hoffmann-La Roche Ltd. 5.5.10.1. Company Overview 5.5.10.2. Product Benchmarking 5.5.10.3. Financial Performance 5.5.10.4. Recent Initiatives 5.5.11. List of other vendors Chapter 6. Methodology and Scope 6.1. Research methodology 6.2. Research Scope & Assumptions 6.3. List of data sources About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business Follow Us:

  6. Your Catalyst To a Lucrative Business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: sales@hexaresearch.com Website - http://www.hexaresearch.com/ Follow Us:

More Related